MAPK3 and hypertrophic cardiomyopathy: In our previous work, ERK1/2 activity was preserved in those with end-stage HF due to hypertrophic cardiomyopathy without significant LV dilation, however, it was depressed in those with HF and severe LV dilation compared with non-failing controls [2].